Physician profile
Danielle A Henry
NPI 1700176856
$1,866.78
in general payments reported to CMS, 2019-2025
12 companies · $375 in 2025
The $375 reported for 2025 was more than what a typical Surgical Oncology provider received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $247 · 2020: $119 · 2022: $23.98 · 2023: $112 · 2024: $991 · 2025: $375.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,012 · Travel and Lodging: $465.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,011.87 |
| Travel and Lodging | $465.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Axogen | $1,004.20 | 2024-2025 | Axoguard Nerve Connector, Avance Nerve Graft, Axoguard Ha+ Nerve Protector |
| Medtronic USA, INC. | $174.22 | 2019 | |
| Merck Sharp & Dohme LLC | $164.88 | 2023-2025 | Keytruda, Lynparza |
| Medical Device Business Services, INC. | $100.38 | 2020 | |
| Merit Medical Systems INC | $89.73 | 2025 | Savi Scout |
| Allergan, INC. | $72.40 | 2019 | |
| Endomagnetics LTD | $70.48 | 2023 | Magseed, Magtrace |
| Daiichi Sankyo INC. | $62.15 | 2020-2024 | Enhertu |
| Davol INC. | $53.03 | 2025 | Phasix Mesh |
| Glaxosmithkline, LLC. | $27.16 | 2025 | Jemperli, Zejula |
| Verastem, INC. | $26.68 | 2025 | Avmapki Fakzynja Co-Pack |
| Macrogenics, INC. | $21.47 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.